Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68-71) improves spatial memory in okadaic acid induced tauopathy model rats - PubMed (original) (raw)
. 2017 Jan 29;483(1):585-589.
doi: 10.1016/j.bbrc.2016.12.101. Epub 2016 Dec 18.
Affiliations
- PMID: 27998769
- DOI: 10.1016/j.bbrc.2016.12.101
Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68-71) improves spatial memory in okadaic acid induced tauopathy model rats
Sarada Subramanian et al. Biochem Biophys Res Commun. 2017.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia, characterized by progressive loss of memory and other cognitive functions. The cognitive impairment in patients with AD is closely associated with loss of synapses and the formation of neurofibrillary tangles (NFT) containing hyperphosphorylated tau in the hippocampus. Effective treatment for AD is still not available. In this study, the sequence comprising of residues 50-71 in the N-terminal region of tau, containing theoretically predicted B- and T-cell epitopes in close proximity to pathologically relevant phospho-serine (residue 68) and phospho-threonine (residues 69, 71) was selected as a potential immunotherapeutic peptide. This 22-residue long phospho-peptide (50TPTEDGSEEPGSETSDAKpSpTPpT71) was custom synthesized and its therapeutic potential was tested in experimental rats. For this purpose, adult Sprague-Dawley rats were intranasally treated with okadaic acid (OA), a selective inhibitor of protein phosphatase PP2A. Within a day of OA administration, these rats showed marked impairment in cognitive functions with a significant increase in p-tau/t-tau ratio in the hippocampal homogenates. Passive immunization studies conducted in these OA treated rats with polyclonal anti-phospho-peptide antibodies resulted in a significant improvement in learning and memory functions in Barne's maze task. Further, p-tau levels in the hippocampal homogenates were reduced. In addition, these antibodies effectively prevented the aggregation of recombinant tau in vitro. These results demonstrate that targeting N-terminal region of tau harbouring the phospho-residue cluster 68-71 would be beneficial and may present an effective therapeutic opportunity for AD and other tauopathies.
Keywords: Alzheimer disease; Okadaic acid; Phosphopeptide; Spatial memory; Tau; Tauopathy.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
- Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats.
Yin YY, Liu H, Cong XB, Liu Z, Wang Q, Wang JZ, Zhu LQ. Yin YY, et al. J Alzheimers Dis. 2010;19(2):735-46. doi: 10.3233/JAD-2010-1272. J Alzheimers Dis. 2010. PMID: 20110616 - Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits.
Koss DJ, Robinson L, Mietelska-Porowska A, Gasiorowska A, Sepčić K, Turk T, Jaspars M, Niewiadomska G, Scott RH, Platt B, Riedel G. Koss DJ, et al. Cell Mol Life Sci. 2015 Dec;72(23):4613-32. doi: 10.1007/s00018-015-1949-4. Epub 2015 Jun 13. Cell Mol Life Sci. 2015. PMID: 26070304 Free PMC article. - Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
Dai CL, Chen X, Kazim SF, Liu F, Gong CX, Grundke-Iqbal I, Iqbal K. Dai CL, et al. J Neural Transm (Vienna). 2015 Apr;122(4):607-17. doi: 10.1007/s00702-014-1315-y. Epub 2014 Sep 19. J Neural Transm (Vienna). 2015. PMID: 25233799 - Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Panza F, et al. Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review. - Immunotherapy for tauopathies.
Gu J, Sigurdsson EM. Gu J, et al. J Mol Neurosci. 2011 Nov;45(3):690-5. doi: 10.1007/s12031-011-9576-5. Epub 2011 Jul 8. J Mol Neurosci. 2011. PMID: 21739165 Free PMC article. Review.
Cited by
- AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.
Borreca A, Latina V, Corsetti V, Middei S, Piccinin S, Della Valle F, Bussani R, Ammassari-Teule M, Nisticò R, Calissano P, Amadoro G. Borreca A, et al. Mol Neurobiol. 2018 Oct;55(10):8124-8153. doi: 10.1007/s12035-018-0974-3. Epub 2018 Mar 5. Mol Neurobiol. 2018. PMID: 29508283 - Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models.
Corsetti V, Borreca A, Latina V, Giacovazzo G, Pignataro A, Krashia P, Natale F, Cocco S, Rinaudo M, Malerba F, Florio R, Ciarapica R, Coccurello R, D'Amelio M, Ammassari-Teule M, Grassi C, Calissano P, Amadoro G. Corsetti V, et al. Brain Commun. 2020 Apr 6;2(1):fcaa039. doi: 10.1093/braincomms/fcaa039. eCollection 2020. Brain Commun. 2020. PMID: 32954296 Free PMC article. - Tau-targeting therapies for Alzheimer disease.
Congdon EE, Sigurdsson EM. Congdon EE, et al. Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z. Nat Rev Neurol. 2018. PMID: 29895964 Free PMC article. Review. - Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies.
Florenzano F, Veronica C, Ciasca G, Ciotti MT, Pittaluga A, Olivero G, Feligioni M, Iannuzzi F, Latina V, Maria Sciacca MF, Sinopoli A, Milardi D, Pappalardo G, Marco S, Papi M, Atlante A, Bobba A, Borreca A, Calissano P, Amadoro G. Florenzano F, et al. Oncotarget. 2017 Apr 22;8(39):64745-64778. doi: 10.18632/oncotarget.17371. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029390 Free PMC article. - Recent advances in tau-directed immunotherapy against Alzheimer's disease: an overview of pre-clinical and clinical development.
Ng PY, Chang IS, Koh RY, Chye SM. Ng PY, et al. Metab Brain Dis. 2020 Oct;35(7):1049-1066. doi: 10.1007/s11011-020-00591-6. Epub 2020 Jul 6. Metab Brain Dis. 2020. PMID: 32632666 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical